How much revenue does IMV make?

IMV reported $0 in revenue for fiscal year 2022.

What companies are similar to IMV?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Hemp Naturals, Inc. (HPMM), Life Stem Genetics Inc. (LIFS), Anbc, Inc. (SYUP), Green Hygienics, Inc. (GRHY).

IMV Inc. (IMVIF) Stock

About IMV Inc.

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX, an immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymp...

At a glance

IMV reported revenue of $0 for fiscal year 2022, and net income of -$37.99 million.

Figures from company filings; latest fiscal year ended December 31, 2022.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.